Christina Cook Robinson, PharmD
Dr. Christina Cook Robinson is a PharmD with a dynamic background spanning health systems practice, and regulatory strategy. At Kaiser Permanente, she has managed multi-therapeutic and oncology specialty access for patients with NSCLC, HER2+ metastatic breast cancer, and ovarian cancer, while advancing equity by identifying Phase III clinical trial candidates among underserved populations. Her regulatory experience includes rotations at the FDA’s Office of Pharmaceutical Quality, AstraZeneca, Johnson & Johnson Innovative Medicine, Rallybio, and Alnylam Pharmaceuticals, where she has contributed to submission modernization, quality and risk mitigation, advisory board strategy, and global trial operations. Her peer-reviewed CME publication on polypharmacy further reflects her commitment to clinical excellence and improved patient outcomes.
Dr. Cook Robinson holds a B.S. in Biological Sciences from Bowie State University and earned her Doctorate from Howard University College of Pharmacy (HUCOP), where she served as a Curriculum Board Ambassador, Program Director of the Industry Pharmacists Organization (IPhO), and Dean-selected Co-Lead of HUCOP’s first DEIA Task Force. She has also served as Vice Chair of the Women in Bio “MAPS” Mentorship Program, Capitol Region Chapter, and Co-Lead of Kaiser Permanente’s Professional African American Association Business Resource Group.
Dr. Cook Robinson is building a career at the forefront of regulatory strategy and portfolio evolution across the full arc of drug development, with the long-term goal of serving as Chief Regulatory Officer. She views regulatory science as a critical lever for translating scientific discovery into safe, effective, and equitable therapeutic delivery. As a driver of process-improvement, she is drawn to identifying inefficiencies and redesigning them into measurable impact. Across the product lifecycle, she is committed to advancing modernization, rigor, and results that strengthen public health outcomes and expand global access to therapies.